Nextcea Patent Suit Targets Lipotype Fat-Based Diagnostic Tests

Lipotype Inc.’s tests that analyze specific fats in the body use Nextcea Inc.'s patented methods for diagnosing certain medical conditions by testing for a specific biomarker without permission, a federal lawsuit says.

Lipotype’s BMP Analysis Services infringe Nextcea’s US Patent No. 8,313,949, according to a complaint filed Tuesday in the US District Court for the District of Massachusetts. Bloomberg Law estimates the patent will expire in January 2031.

“The damage and threat to the Nextcea’s business and intellectual property has become untenable,” Nextcea said. The suit seeks damages and a permanent injunction.

Nextcea’s proprietary biomarker, di-22:6-BMP, is a unique ...